Discussion
myocardial damage, ischemia, pneumonia, infarct
PNEUMONIA, ACUTE DISEASES, ISCHEMIA, INFLAMMATION, INFARCT
The aim of this trial is to investigate whether administration of a single-pulse-dose glucocorticoid pulse injection in the pre-hospital setting reduces final infarct size and limits reperfusion injury in patients with STEMI. We expect to find a 20% reduction in final infarct size measured by CMR at 3 months following STEMI.Glucocorticoid has been used for decades, and recent trials have shown that the administration of glucocorticoid in acute diseases such as pneumonia and COVID-19 improves prognosis significantly [Inflammation and thus myocardial damage are initiated both by ischemia itself, immediately after occlusion of the artery and subsequently after reperfusion. Up to 60% of patients with STEMI have reperfusion in the pre-hospital setting due to effective antithrombotic treatment with heparin and aspirin, and reperfusion severely adds to the inflammatory burden [